Mutations in the gene CSDE1 lead to a constellation of developmental delays and conditions, including autism, according to a new study.

Some traits of fragile X syndrome may be due to problems with mitochondria, the cell’s energy factories.

Drug after drug has failed in clinical trials for fragile X syndrome. A new study provides an explanation — a decrease in the drugs’ effectiveness over time — and points to a new strategy that could circumvent this problem.

New findings hint at why drugs that work in mouse models of fragile X syndrome have not been effective in people.

Problems with the minute ‘factories’ that yield energy for cells — the mitochondria — may contribute to learning problems and other traits of fragile X syndrome.

Fragile X syndrome is a leading genetic cause of autism. People who have either condition often share certain traits, such as difficulties in social situations.

The protein missing in fragile X syndrome, FMRP, facilitates the production of hundreds of unusually large proteins, some of which are linked to autism.